Altre lingue Moberg Pharma AB

Azioni

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 17:29:44 03/05/2024			Variaz. 5gg	Var. 1 gen.
36,58 ^SEK	-0,76%		+10,31%	+140,66%

23/04	Moberg Pharma AB (Publ) annuncia un aggiornamento sul lancio di Mob-015	CI
08/04	Moberg Pharma AB (Publ) presenta la richiesta di includere un ulteriore fornitore di terbinafina	CI

Moberg Pharma : Launch update for MOB-015	23/04
Moberg Pharma : Launch update for MOB-015	23/04
Moberg Pharma AB Announces Launch Update for Mob-015	23/04
Notice of Annual General Meeting in Moberg Pharma AB (publ)	12/04
Moberg Pharma Annual report for 2023	12/04
Moberg Pharma : Corporate Governance Report 2023	12/04
Moberg Pharma : Application submitted to include an additional terbinafine supplier	08/04
Moberg Pharma AB Submits Application to Include an Additional Terbinafine Supplier	08/04
Certain Ordinary Shares of Moberg Pharma AB are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	26/02
The Nomination Committee's proposal to the Annual General Meeting 2024	19/02
Moberg Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/02
Moberg Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	13/02
MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication	07/02
Moberg Pharma's Interim report January - September 2023	07/11
Moberg Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Moberg Pharma strengthens the organization	07/11
Moberg Pharma Announces Leadership Changes	07/11
Moberg Pharma's Nomination Committee appointed	17/10/23
Moberg Pharma AB Appoints Nomination Committee	17/10/23
MOBERG PHARMA HAS COMPLETED ENROLLMENT TO THE PHASE 3 STUDY FOR MOB-015 IN NORTH AMERICA	09/10/23

Non ci sono risultati per questa ricerca